B+
Bull case
20%
Probability
Target price
$31.24
+223.7% vs current
PHAT
PhathomCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$15.62
+61.9% vs current
B-
Bear case
30%
Probability
Target price
$7.81
-19.1% vs current
AI sentiment snapshot
Latest data as of 2025-11-29
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Market tone remains cautious after the May 2024 $130M offering; investors focus on cash runway and near-term binary readouts. Low coverage and modest institutional ownership amplify volatility; technical selling has pressured the share price, while long-term re-rating depends on positive data or non-dilutive deals.
RankAlpha Sentiment AI - 2025-11-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventClinical readout for lead GI programHigh impact
Top-line efficacy/safety readout from lead program could re-rate shares materially; outcome binary and will affect commercial outlook.
-eventPartnership / licensing announcementHigh impact
A commercial or regional licensing deal would de‑risk development spend and could provide near‑term non‑dilutive capital.
-catalystNeed for additional financingHigh impact
Biotech cash burn may force equity financing or dilution within 12 months if milestones are missed or partners are not secured.
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-29 • Updated nightlySource: Internal modelMethodology